The efficacy of adjunctive topical calcipotriol 0.005% cream was evaluated in psoriasis vulgaris (PV) and psoriatic arthritis (PsA) patients partially responsive to etanercept. One hundred and twenty patients (mean age 48 years) with PV and PsA were enrolled. A 50-mg s.c. etanercept dose was administered twice weekly for 12 weeks, followed by 25 mg s.c. twice weekly for 12 weeks. At week 12, 45 patients did not achieve a Psoriasis Area and Severity Index decrease of at least 50% from baseline (PASI-50) and were administered calcipotriol cream twice daily for 4 weeks, then once daily for 8 weeks, together with etanercept. At week 24, of the 45 patients in the ...